摘要
目的分析氟哌噻吨美利曲辛联合雷贝拉唑治疗反流性食管炎的临床效果及对患者HAMD评分的影响。方法将本院2015年3月至2016年3月收治的98例反流性食管炎患者随机分为观察组和对照组,各49例。对照组予以雷贝拉唑治疗,观察组在此基础上予以氟哌噻吨美利曲辛治疗。比较两组患者治疗效果、症状改善评分及治疗前、后HAMD评分。结果观察组治疗总有效率为95.92%,显著高于对照组的79.59%(P<0.05)。观察组的症状改善评分均低于对照组(P<0.05)。治疗后,两组患者HAMD评分均降低,且观察组低于对照组(P<0.05)。结论针对反流性食管炎患者采用氟哌噻吨美利曲辛与雷贝拉唑合并用药进行治疗,不仅能够改善患者的嗳气、腹痛等症状,而且可以改善患者的HAMD评分,值得推广。
Objective To analyze the clinical effect of flupenthixol melitracen combined with rabeprazole in the treatment of reflux esophagitis and its impact on HAMD scores. Methods A total of 98 patients with reflux esophagitis admitted in our hospital from March 2015 to March 2016 were randomly divided into observation group and control group,with 49 cases in each group. The control group was treated with rabeprazole, and the observation group was treated with flupenthixol melitracen based on the control group. The treatment effects, symptom improvement scores and HAMD scores before and after treatment were compared between the two groups. Results The total effective rate of treatment in the observation group was 95.92%, which was obviously higher than 79.59% in the control group（P〈 0.05）. The symptom improvement scores of the observation group were lower than those of the control group（P〈 0.05）. After treatment, the HAMD scores of patients in both groups decreased, and that of the observation group was lower than the control group（P〈 0.05）.Conclusion The combination of flupenthixol melitracen and rabeprazole in patients with reflux esophagitis can not only improve the symptoms of belching and abdominal pain, but also improve the HAMD scores of the patients, it is worthy of promotion.
作者
李永红
LI Yong-hong(the People＇s Hospital of Mei county,Baoji 722300,China)
出处
《临床医学研究与实践》
2018年第30期23-24,共2页
Clinical Research and Practice
